乳児期発症の急性骨髄性白血病の治療成績の検討―東京小児がん研究グループ（ＴＣＣＳＧ）１３次および１４次研究より―

DOI 参考文献16件

書誌事項

タイトル別名
  • Treatment Outcome of Infants with Acute Myeloid Leukemia: Results of the Two Consecutive Trials of Tokyo Children's Cancer Study Group
  • Results of the Two Consecutive Trials of Tokyo Children's Cancer Study Group
  • 東京小児がん研究グループ (TCCSG) 13次および14次研究より

この論文をさがす

説明

We evaluated the clinical characteristics and the prognosis of infants with acute myeloid leukemia (AML), excluding Down syndrome and acute promyelocytic leukemia, registered in two consecutive multicenter trials, desig-nated TCCSG M91-13 and M96-14, between 1991 and 1998. Among the infants, 80% of the cases comprised FAB type M4/M5 (58.4%) and M7 (25.0%), which was more than twice as high as non-infant cases. In addition, infants had a karyotypic character distinct from older cases, such as higher incidence of 11q23 abnormalities (20.8%), no cases with t (8;21), etc. There was no significant difference in 5-year event-free survival rates for 24 infant cases and 168 non-infant cases, which were 49.4%±20.2% vs. 55.2%±7.5% (p = 0.46), respectively. Among the infant cases, the proportion of fatal infectious complications was high; 60.0% (3/5) of the events during remission inductio and 41.7% (5/12) of the total events. Careful and effective supportive care for infectious complications is required, especially during remission induction, for the treatment of infants with AML.

収録刊行物

参考文献 (16)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ